Ocugen (NASDAQ: OCGN) raises $15M via warrant exercise, extends runway

(Moderate)

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Ocugen, Inc. reports that an institutional investor partially exercised previously issued warrants and purchased 10,000,000 shares of common stock on March 12, 2026. This warrant exercise generated gross proceeds of $15.0 million for Ocugen. The company states that, based on this cash infusion, it now anticipates its cash runway will extend into the first quarter of 2027, supporting ongoing operations and development plans.

Positive

$15.0 million gross proceeds from warrant exercise strengthen Ocugen’s cash position and provide non-debt capital from an existing institutional investor.
Cash runway extended into the first quarter of 2027, according to Ocugen, which may ease near-term liquidity concerns and support ongoing development plans.

Negative

None.

Insights

Warrant exercise brings $15M cash, extending Ocugen’s runway into early 2027.

Ocugen received $15.0 million in gross proceeds from an institutional investor’s partial exercise of warrants for 10,000,000 common shares. These warrants stem from a registered direct offering completed in August 2025, so this is a follow-on capital inflow rather than a new financing deal.

The company states that this additional cash is expected to extend its operating runway into the first quarter of 2027. For a development‑stage biopharma, added runway can reduce near‑term financing pressure and support clinical and regulatory activities, although the filing does not detail specific programs funded.

Management highlights the forward‑looking nature of its runway expectations and points to risk factors in its SEC reports. Actual outcomes will depend on spending levels, any further capital raises, and operational progress, which will be reflected in future periodic filings.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

What did Ocugen (OCGN) announce in this Form 8-K?

Ocugen announced that an institutional investor partially exercised previously issued warrants to purchase 10,000,000 shares of common stock. This transaction generated $15.0 million in gross proceeds and is expected to extend the company’s cash runway into the first quarter of 2027.

How much cash did Ocugen (OCGN) receive from the warrant exercise?

Ocugen received $15.0 million in gross proceeds from the investor’s partial exercise of warrants. These proceeds result from the purchase of 10,000,000 shares of common stock linked to a registered direct offering originally completed in August 2025.

How many shares were issued in Ocugen’s latest warrant exercise?

The institutional investor purchased 10,000,000 shares of Ocugen’s common stock through a partial exercise of warrants. These warrants were originally issued alongside 20,000,000 shares of common stock in a registered direct offering completed in August 2025.

How does the warrant exercise affect Ocugen’s cash runway?

Ocugen states that the $15.0 million in gross proceeds from the warrant exercise is expected to extend its cash runway into the first quarter of 2027. This suggests additional operational flexibility, though the company cautions that this expectation is forward-looking and subject to risks.

What was the origin of the warrants exercised in Ocugen’s March 2026 transaction?

The exercised warrants were issued in an August 2025 registered direct offering between Ocugen and an institutional investor. That deal included 20,000,000 common shares and warrants to purchase up to an additional 20,000,000 shares of common stock.

Does Ocugen (OCGN) provide any cautions about its cash runway guidance?

Yes. Ocugen labels its expected cash runway into the first quarter of 2027 as a forward-looking statement, subject to numerous risks and uncertainties described in its annual and quarterly SEC reports, particularly under the “Risk Factors” sections.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Accepted by SEC EDGAR 03/20/2026 - 08:00 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15 (d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): March 12, 2026

OCUGEN, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-36751		04-3522315
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

11 Great Valley Parkway

Malvern, Pennsylvania 19355

(484) 328-4701

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value per share		OCGN		The Nasdaq Stock Market LLC (The Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 Other Events.

As previously disclosed, in August 2025, Ocugen, Inc. (“Ocugen”) closed a registered direct offering, pursuant to a securities purchase agreement with an institutional investor (the “Investor”), for the purchase and sale of 20,000,000 shares of common stock, $0.01 par value per share (“Common Stock”), and warrants to purchase up to an aggregate of 20,000,000 shares of Common Stock.

On March 12, 2026, the Investor purchased 10,000,000 shares of Common Stock upon the partial exercise of its warrants for the gross proceeds of $15.0 million to Ocugen. Ocugen anticipates that proceeds from such partial exercise of the warrants will extend its cash runway into the first quarter of 2027.

Cautionary Note Regarding Forward Looking Statements

This Current Report on Form 8-K (“Form 8-K”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Ocugen’s expected cash runway into the first quarter of 2027, which are subject to risks and uncertainties. Ocugen may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from Ocugen’s current expectations. These risks and uncertainties are more fully described in Ocugen’s annual and periodic filings with the Securities and Exchange Commission (“SEC”), including the risk factors described in the section entitled “Risk Factors” in the annual and quarterly reports that Ocugen files with the SEC. Any forward-looking statements that Ocugen makes in this Form 8-K speak only as of the date of this Form 8-K. Except as required by law, Ocugen assumes no obligation to update forward-looking statements contained in this Form 8-K, whether as a result of new information, future events, or otherwise, after the date of this Form 8-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 19, 2026

OCUGEN, INC.

By:	/s/ Shankar Musunuri
	Name: Shankar Musunuri
	Title: Chairman, Chief Executive Officer, & Co-Founder

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents